# AXTI earnings call intelligence LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/AXTI) · [Earnings tab](https://www.lopjlb.com/stock/AXTI?tab=earnings) Updated: 2026-09-07T02:48:42 Quarters analyzed: 8 ## Cross-quarter narrative Across the eight calls AXTI moved from margin compression driven by soaring germanium costs and modest Q4 guidance in late‑2024 to a pronounced margin recovery by mid‑2026 as product mix shifted to higher‑margin indium‑phosphide wafers and operating expenses were trimmed. Demand remained robust, initially highlighted in data‑center and silicon‑photonic markets and later expanding into AI‑driven data‑center upgrades, lidar and PON, supporting a growing backlog that topped $100 million. Export‑permit constraints emerged in early‑2025 and have persisted, repeatedly delaying shipments of both indium‑phosphide and gallium‑arsenide and adding revenue timing risk. Capacity expansion accelerated, with announced double‑up of indium‑phosphide capacity, 6‑inch line development and a new Beijing fab slated for 2027. Inventory levels fell from a peak above $77 million to a more controlled position, while cash was bolstered by a $632 M raise. The Tongmei IPO remained at risk throughout, shifting from Shanghai to Hong Kong. Germanium pricing pressure and customer concentration concerns have been recurring, while raw‑material joint‑venture performance moved from on‑track to delivered stability. ## Latest CallCard · Q2 AXT posted record Q2 revenue and margin as indium phosphide demand surges, capacity expansion is ahead of schedule, but reliance on export permits and backlog conversion adds uncertainty. **Guidance:** maintained — Q3 revenue guidance of $66 million is presented with confidence but notes permit timing uncertainty. **Tone:** mgmt 0.8 · Q&A pressure 0.6 · divergence 0.4 Management emphasizes an inflection point with extremely strong demand and capacity expansion ahead of schedule. ### Demand visibility Backlog exceeds $100 million and demand outpaces supply across AI data center applications. Backlog >$100 M, visibility extending 3‑4 quarters, strong demand for 100G/1.6T transceivers, China accounted for >50% of Q2 revenue, expected 40‑60% split long‑term. ### Margins / costs Non‑GAAP gross margin rose to 45% driven by volume and mix. Margin improvement stems from higher indium phosphide volume, larger‑diameter substrates and productivity gains; management targets margins in the 50% range. ### Capital allocation Cash bolstered by $632 M offering and prepayments; limited incremental CapEx. Cash $749 M, prepayments $22.3 M (Casella) and $25.4 M (Coherent); capacity gains largely from productivity, not large new CapEx spend. ### Milestones - **Indium phosphide capacity doubling 2026** [on_track]: Management says they are ahead of schedule on the capacity expansion. - **6‑inch indium phosphide capability** [on_track]: Progress reported on developing 6‑inch substrates, a more difficult volume product. - **Tongmei IPO on Hong Kong Exchange** [on_track]: IPO moved from STAR Market to Hong Kong, expected to take about a year. - **Long‑term supply agreements (Casella, Coherent, Lumentum)** [delivered]: Agreements signed with significant prepayments to support demand. - **Jingmei raw‑material JV refining high‑purity indium** [on_track]: Provides guaranteed supply for indium phosphide substrates. ### Fears / risks - **Regulatory/Permits**: Uncertainty around export permits could limit ability to ship orders and affect revenue timing. - **Backlog Visibility**: Backlog size is disclosed only qualitatively; conversion to revenue depends on permit approvals. - **Capacity Constraints**: Demand outpaces supply; ability to scale capacity quickly is critical. - **China Market Dependence**: Over 50% of Q2 revenue came from China, exposing the company to regional policy and permit risks. - **Competitive Landscape**: Limited number of high‑quality indium phosphide suppliers, but rivals could erode market share. - **CapEx Allocation**: Management claims limited additional CapEx, but rapid capacity growth may require unforeseen spending. - **Supply Chain**: Reliance on raw‑material JV for indium supply; any disruption could impact production. - **Pricing Pressure**: Potential for price appreciation exists, but margin targets depend on volume and mix. ### Key quotes > “Revenue for the second quarter of 2026 is $47.6 million. This is the highest quarterly revenue in AXT history.” > “We are committed to doubling our indium phosphide capacity in 2026 and I am pleased to report that we are ahead of the schedule in that effort.” > “So that is $60 million, thereabouts.” — Timothy J. Bettles > “We should definitely be targeting a number that begins with a 5.” > “There is actually not a lot of additional CapEx spend here.” ## Quarter one-liners - **2026 Q2:** AXT posted record Q2 revenue and margin as indium phosphide demand surges, capacity expansion is ahead of schedule, but reliance on export permits and backlog conversion adds uncertainty. - **2026 Q1:** AXT posted Q1 2026 revenue of $26.9M, improved margins to ~30% and announced aggressive Indium Phosphide capacity expansion, but export‑permit timing and geopolitical factors add uncertainty. - **2025 Q4:** AXT reported Q4 revenue down to $23M, highlighted export permit bottlenecks as the main growth constraint while noting a strong indium phosphide backlog, 25% capacity lift and plans to double capacity by year‑end. - **2025 Q3:** AXTI reports strong Q3 revenue growth driven by indium phosphide demand, but export‑permit timing and geopolitical risk keep guidance cautious. - **2025 Q2:** AXT reported Q2 revenue of $18M, improved margins to 8.2% non‑GAAP, but highlighted export‑permit delays for gallium arsenide and indium phosphide that cut shipments, while forecasting sequential Q3 revenue growth to $19‑21M. - **2025 Q1:** AXTI Q1 2025 showed a revenue dip and negative margins due to export restrictions and yield issues, but management sees upside in China data‑center, lidar and a quick permit rollout. - **2024 Q4:** AXTI posted 31% YoY revenue growth but Q4 margins fell to 17.9% non‑GAAP as recycling benefits waned and export controls delay $4‑5M of indium phosphide sales in Q1, while R&D targets low‑EPD breakthroughs for 2025 growth. - **2024 Q3:** AXTI posted Q3 revenue of $23.6M, saw margin pressure from soaring germanium prices, highlighted growth in indium phosphide data‑center demand, progress on a new silicon‑photonic product and Tongmei IPO, and reaffirmed modest Q4 guidance. ## Theme arcs - **Export permit constraints** (deteriorating): Permit delays repeatedly limited shipments of key products - **Margin trajectory** (improving): Gross margin rose from sub‑20% to 45% as mix shifted to higher‑margin wafers - **Demand strength** (improving): Backlog grew to >$100M and demand across AI data‑center, lidar and PON stayed strong - **Capacity expansion** (improving): Indium‑phosphide capacity doubled and 6‑inch line progressed - **Inventory reduction** (improving): Inventory fell from $77.7M to lower levels as drawdown continued - **Germanium pricing pressure** (deteriorating): Raw‑material cost spikes repeatedly compressed margins - **Customer concentration** (deteriorating): Top‑5 customers’ share rose to ~45% with two >10% - **IPO uncertainty** (stable): Tongmei IPO remained at risk, later shifting exchanges - **Raw‑material JV performance** (improving): Joint‑venture revenue stability delivered - **Silicon photonics engagement** (stable): Engagement stayed on‑track since first mention ## Fear persistence - **Export permit risk** [recurring]: Repeated delays affect shipment timing - **Geopolitical risk** [recurring]: China‑US tensions impact export controls - **Germanium pricing pressure** [recurring]: Raw‑material cost spikes compress margins - **Customer concentration** [recurring]: Top customers represent increasing revenue share - **IPO regulatory risk** [recurring]: Tongmei listing remains uncertain - **Yield/manufacturing challenges** [resolved]: Yield issues noted in early 2025, not mentioned later ## Guidance path 2024 Q3:maintained → 2024 Q4:maintained → 2025 Q1:maintained → 2025 Q2:raised → 2025 Q3:maintained → 2025 Q4:vague → 2026 Q1:maintained → 2026 Q2:maintained --- Research context only. Not personalized investment advice. API: `GET /bff/api/bigfive/earnings-intel/AXTI`